Yumz Lab Review: 'Stock Up Before the Hemp Ban' Is the Worst Possible Advice

Take the legal facts first, because Yumz Lab has them substantially right. Public Law 119-37, enacted November 12, 2025, redefines hemp with effect from November 12, 2026. The new definition excludes cannabis products containing more than 0.4 milligrams of total THC per container, and excludes cannabinoids not capable of being naturally produced by the plant or that were synthesised. Excluded products fall under the Controlled Substances Act and are treated as marijuana. (Congressional Research Service, IF13136 and LSB11381.) So yes, the products Yumz Lab sells are affected, and yes, it will have to stop selling them. Every item on its THCA and delta-9 menu is orders of magnitude over a 0.4 mg per-container cap. The company is not scaremongering about that part. Here is where the advice goes wrong. The statute changes what the product is, not just who may sell it. After November 12, 2026, a jar of high-THC gummies is not lawful hemp that you happen to have bought early. It is, federally, a controlled substance in your house. There is no consumer grandfather provision. Nothing in the redefinition exempts inventory already in private hands. A stockpile is not a legal position. The risk is asymmetric. The seller's downside is lost revenue. The buyer's downside is possessing a controlled substance, with consequences that scale with quantity — and "stock up" is an instruction to increase quantity. And state law is separate and often stricter, already, today. The site itself notes it ships to select states only, which is an acknowledgement that a meaningful number of states already prohibit these products. What we would actually advise. Do not buy more than you would normally use before November. If you have a stock on the date, the sensible course is to dispose of it, not to hold it. A merchant with three months of runway has an obvious incentive to tell you to buy deeply now. That incentive is not aligned with yours.

This is the most serious issue on the site and it is independent of the hemp question. What Yumz Lab publishes about its mushroom line, in its own words: It uses "a proprietary blend that's different than psilocybin and has no clinical evidence for its use as a therapy." The product "produces similar effects to magic mushrooms" and is "completely free from Psilocybin, Psilocin, and Psilacetin." "To preserve the uniqueness of our offering, the exact composition of the active ingredients remains a confidential secret." "NOOTROPICS WARNING: RISK OF HALLUCINATIONS, TRIGGERING OF SUPPRESSED TRAUMAS AND LOSS OF MOTOR SKILLS." Read those together. The company is selling a product it says causes hallucinations and loss of motor skills, while declining to say what is in it. There is no version of that which is acceptable in a food product. You cannot check for an interaction with your medication, you cannot avoid an allergen, and if you have a bad reaction, neither you nor the emergency department treating you knows what to look for. And the published evidence on precisely this product category is not reassuring. The CDC's Morbidity and Mortality Weekly Report, volume 73, number 28 (July 18, 2024), published Notes from the Field: Schedule I Substances Identified in Nootropic Gummies Containing Amanita muscaria or Other Mushrooms — Charlottesville, Virginia, 2023–2024. Its findings: Five people required hospital evaluation after ingesting nootropic gummies labelled as containing Amanita muscaria. Five brands were analysed. Three contained unlabelled psilocybin or psilocin — DEA Schedule I substances that were not on the label. That is the risk in concrete form: products in this exact category, marketed this exact way, have been found to contain controlled substances their labels did not declare, and people were hospitalised. A confidential-secret formulation is unverifiable by definition, which is precisely the condition under which that happens. Separately, Amanita muscaria itself is not a benign ingredient. Its active compounds, ibotenic acid and muscimol, produce dose-dependent central nervous system effects, and the clinical literature documents acute toxicity including severe cases. It is not psilocybin, but not-psilocybin is not the same as safe. And a free mushroom chocolate bar ships with every order. That means a psychoactive product a customer did not choose arrives in a household that may include children, other adults, or pets. Unrequested psychoactive product in the post is a hazard, not a gift.

The homepage carries a block headed 2026 VERIFIED STUDY — YUMZ DELTA 9 THC GUMMIES SLEEP REPORT, with the following figures: 94% reported sleep onset within 45–60 minutes of dosing 80% reported fewer middle-of-the-night awakenings 91% reported zero fog or grogginess upon waking Participants: 1,248 verified buyers. Duration: 180 days (Oct '25 – Mar '26). Dosage: half a gummy, 5 mg delta-9. With a link to a full 12-page report. This is not a study, and calling it verified does not make it one. The participants are self-selected buyers. Everyone in the sample chose to buy the product, kept using it, and stayed reachable. People who tried it, disliked it, and left are structurally absent. This alone inflates every number. There is no control group and no blinding. For sleep — one of the most placebo-responsive outcomes in medicine — this is disqualifying. You cannot distinguish the drug from the expectation of the drug without a comparator. The outcomes are self-reported and unvalidated. Zero reported fog is not a measurement; polysomnography and validated instruments exist for a reason. 91% reporting no next-day grogginess is, on its face, implausible for a 5 mg THC dose taken at night. Next-day impairment is one of the better-documented effects of evening cannabinoid dosing. No protocol, no ethics oversight, no pre-registration, no independent analysis — and the report is published by the company selling the product. What the actual evidence says about THC and sleep. Cannabinoids can shorten time to fall asleep for some people in the short term. The medium-term picture is worse than the marketing: tolerance develops, REM sleep is suppressed, and discontinuation commonly produces rebound insomnia and vivid dreams, which is one reason people find themselves unable to stop. Using an intoxicant nightly to sleep is a well-worn route into dependence on it for sleep. If you have persistent insomnia, the first-line treatment with the strongest evidence is CBT-I — cognitive behavioural therapy for insomnia — not a gummy. It outperforms medication over the long run and has no tolerance curve.

On THCA flower. The site's own FAQ is unusually candid: THCA "converts straight into regular Delta-9 THC via a process called decarboxylation" and is "identical in appearance, smell, and punch to dispensary-grade bud, while remaining federally compliant under the Farm Bill." That is an accurate description of what the product is and an explicit statement of the arbitrage it relies on. It is also a precise description of what P.L. 119-37 was written to end — the new test is total THC, which captures the acid form. On the pressure tactics. The homepage runs an EXPIRING SOON discount marquee repeated ten times, an item-level counter reading 87 left, and the hemp-ban banner above everything. Urgency stacked this densely is a sales technique, not information. The one genuinely time-limited fact on the page — the November statutory change — is being used as a promotional device. On lab testing. The site has a Lab Results page and claims 100% lab-verified, zero heavy metals or pests, and cold-cured COAs, contrasted against street and local shops with untested product and no COAs. Third-party testing is genuinely the right thing to look for — but it must be a batch-matched certificate of analysis from an accredited lab, dated, and covering potency, pesticides, heavy metals, residual solvents and microbials. Verify the COA matches the batch code on the item you receive, and note that a COA on the THCA line says nothing whatever about the mushroom line, whose composition the company declines to disclose. Prices observed: flower at $150 per ounce and $600 for five ounces, eighths at $29.99, hash at $27.99 to $30.99 per gram, carts $19.99 to $29.99, mushroom gummies $31.99 to $40.00. Age and access: the site states 21+ only and ships to select states. Age-gating on hemp sites is typically a self-declared checkbox, which is not a control.

Is the hemp ban real? The federal definition of hemp changes on November 12, 2026 under P.L. 119-37, excluding products with more than 0.4 mg total THC per container. Excluded products are regulated as marijuana under the Controlled Substances Act. It is a redefinition rather than a ban, but the practical effect on this catalogue is the same. Should I stock up before then? No. There is no consumer grandfather clause. After the date, excluded products are controlled substances regardless of when you bought them, and a larger stock is a larger exposure. Is THCA flower legal now? Under the 2018 Farm Bill's dry-weight test, sellers have argued it is. Several states prohibit it regardless, and the November change is drafted in terms of total THC, which captures the acid form. What is in the mushroom gummies? The company states the exact composition of the active ingredients is a confidential secret. It says the products are free of psilocybin, psilocin and psilacetin, and warns of hallucination risk and loss of motor skills. Is that safe? We would not take it. CDC MMWR reporting found three of five tested brands of Amanita-labelled nootropic gummies contained unlabelled Schedule I substances, with five people hospitalised. Why is a free mushroom chocolate bar included? It is a promotional add-on shipped with all orders. A psychoactive product arriving unrequested in a household is a hazard — store it as you would a medicine, or refuse it. Is the 94% sleep figure meaningful? No. It is a survey of self-selected buyers with no control group, no blinding and unvalidated self-reported outcomes. Will these products fail a drug test? Yes. Every THC product here is intoxicating and detectable. What should I do about persistent insomnia? CBT-I is the first-line treatment with the best long-term evidence. Speak to a clinician. What if someone has a bad reaction? Contact Poison Control on 1-800-222-1222 in the US, or emergency services if the person is unresponsive, having a seizure, or having difficulty breathing. Take the packaging with you.